Interferon

Type: Keyphrase
Name: Interferon
First reported 3 hours ago - Updated 2 hours ago - 2 reports

Research and Markets: Global Hepatitis C Therapeutics in Major Developed Markets 2013-2019

DUBLIN--(BUSINESS WIRE)--Apr. 23, 2014-- Research and Markets (http://www.researchandmarkets.com/research/q3nxmh/hepatitis_c) has announced the addition of the report to their offering.The global market has the potential to grow to a value of $18.6 billion ... [Published BusinessWeek - 2 hours ago]
First reported Apr 22 2014 - Updated 6 hours ago - 4 reports

Combination tablet offers alternative to interferon for hepatitis C genotype 1 infection

A fixed-dose tablet containing ledipasvir and sofosbuvir is highly effective and well tolerated in a broad range of patients with hepatitis C virus (HCV) genotype 1 infection, show results of two phase III randomised controlled trials.Findings f...Related ... [Published BioPortfolio - 7 hours ago]
First reported 20 hours ago - Updated 20 hours ago - 2 reports

The World Market for Biosimlars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition

(PR Newswire) Reportlinker.com announces that a new market research report is available in its catalogue: ... ... [Published Individual.com - 20 hours ago]
First reported 22 hours ago - Updated 22 hours ago - 1 reports

Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season

Background: Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system which responds to therapies targeting circulating immune cells. Objective: Our aim was to test if the T-cell activation gene expression pattern (TCAGE) we ... [Published Multiple Sclerosis Journal current issue - 22 hours ago]
First reported Apr 21 2014 - Updated 23 hours ago - 1 reports

3 Stocks To Capitalize On Advances In Hepatitis C Treatment

Summary150 million people throughout the world suffer from hepatitis C. There are a number of treatments for hepatitis C currently under development. Gilead Sciences treatment is highly effective and first to market. Merck, Bristol-Myers Squib and ... [Published Seeking Alpha - Apr 21 2014]
First reported Apr 21 2014 - Updated Apr 21 2014 - 1 reports

PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C

Ribavirin (RBV) remains part of several interferon-free treatment strategies even though its mechanisms of action are still not fully understood. One hypothesis is that RBV increases responsiveness to type I interferons. Pegylated Interferon alpha (PEG-IFNa) ... [Published PLoS medicine - Apr 21 2014]
First reported Apr 21 2014 - Updated Apr 21 2014 - 1 reports

MxA levels and interferon-beta response

Can we predict who are responders and non-responders to interferon-beta? #MSBlog #MSResearch "Interferon-beta is a cytokine (intracellular immune messenger) that binds to its receptors on cells to induce specific biological effects. It is one of the ... [Published Multiple Sclerosis Research - Apr 21 2014]
First reported Apr 19 2014 - Updated Apr 19 2014 - 1 reports

Strong sense of awareness needed

Researchers have found that your brain can produce substances that improve your physical health. The brain produces endorphins – natural painkillers – and interferon, which combat infections, viruses, and even cancer. ... [Published Tanzania Citizen - Apr 19 2014]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

EASL 2014: Prolonged Pegylated Interferon + Tenofovir Does Not Prevent Hepatitis Delta Relapse

Details Category: Hepatitis Delta (HDV) Published on Friday, 18 April 2014 00:00 Written by Liz HighleymanTreating hepatitis B patients with hepatitis delta virus (HDV) coinfection using pegylated interferon plus tenofovir (Viread) for 96 weeks may ... [Published HIV and Hepatitis.com - Apr 18 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Serious Side Effect Seen in MS Patients on Interferon Beta

Cases of unexpected, serious, and even fatal thrombotic microangiopathy (TMA) linked to use of a new serum-free formulation of interferon beta ( Rebif , Merck) have emerged in patients with multiple sclerosis (MS).In a Letter to the Editor published in ... [Published General Medicine eJournal - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 17 2014 - 3 reports

BMS combination cures 90% of genotype 1b hepatitis C in 24 weeks

A combination of two direct-acting antivirals developed byBristol-Myers Squibb (BMS) cured 90% of previously untreated people with genotype 1b hepatitis Cinfection in 24 weeks, without the need for pegylated interferon or ribavirin,Prof. Michael Manns ... [Published Aidsmap - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 2 reports

Research and Markets: World Market for Biosimilars to 2017: EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/xgx3p4/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" ... [Published Business Wire Health News - Apr 16 2014]

Quotes

...market is worth billions, and Express Scripts forecasts that the US will spend 1,800% more on treatments in 2016 than it did last year, noting that "no major therapy class has experienced this high of a spending increase" in the 21 years it has measured such data
...regimens," said Brian Daniels , MD, senior vice president, Global Development and Medical Affairs, Research and Development, Bristol-Myers Squibb . "In addition to the Hallmark-Dual study, we are pleased to be presenting data at EASL on our investigational 3DAA fixed-dose- combination, as well as daclatasvir in combination with other HCV compounds."
Original Article: NEXT ARTICLE More From BioPortfolio on "Combination tablet offers alternative to interferon for hepatitis C genotype 1 infection"
...3 billion in revenue (from hepatitis C drug Sovaldi) in the first 3 months on the market," said Sanford Bernstein analyst Geoffrey Porges. "People's numbers are going to go up dramatically for this year and next for Gilead."

More Content

All (758) | News (631) | Reports (0) | Blogs (110) | Audio/Video (0) | Fact Sheets (3) | Press Releases (9)
sort by: Date | Relevance
AbbVie files hep C combo in the US [Published Pharma Times - 2 hours ago]
Research and Markets: Global Hepatitis C Therap... [Published BusinessWeek - 2 hours ago]
Global Hepatitis C Therapeutics in Major Develo... [Published Individual.com - 3 hours ago]
Molecular-Based Techniques Diagnose Leprosy [Published Lab Medica - 4 hours ago]
BRISTOL MYERS SQUIBB : Showcases Phase III Data... [Published 4 Traders - 6 hours ago]
Combination tablet offers alternative to interf... [Published BioPortfolio - 7 hours ago]
Gilead Sciences' CEO Discusses Q1 2014 Results ... [Published Seeking Alpha - 8 hours ago]
Cloning and Expression of Retinoic Acid–Induced... [Published Lab Medicine - 8 hours ago]
UPDATE 2-Gilead profit triples, hepatitis C dru... [Published Reuters - 12 hours ago]
Sunitinib-related fatigue occurs early then tai... [Published News-Medical.Net - 14 hours ago]
GILEAD SCIENCES' : Results Boosted by Hepatitis... [Published 4 Traders - 14 hours ago]
LMKB/MARF1 Localizes to mRNA Processing Bodies,... [Published PLoS medicine - 14 hours ago]
UPDATE 1-Gilead profit triples, hepatitis C dru... [Published CNBC - 14 hours ago]
Gilead Sciences Drops Jaws With a 209% Increase... [Published Motley Fool Discussion Boards - 14 hours ago]
Whole-blood transcriptomic profiling highlights... [Published Arthritis & Rheumatism - 15 hours ago]
Determination of Toll-Like Receptor-Induced Cyt... [Published Sexual Development - 17 hours ago]
Patients with advanced liver disease and hepati... [Published PJ Online - 17 hours ago]
Combination tablet offers alternative to interf... [Published PJ Online - 17 hours ago]
AbbVie heads to the FDA with its hep C combo in... [Published FierceBiotech - 20 hours ago]
The World Market for Biosimlars (EPO, G-CSF, HG... [Published Individual.com - 20 hours ago]
The World Market for Biosimlars (EPO, G-CSF, HG... [Published PR Newswire: Entertainment & Media - 20 hours ago]
Ribosomal protein S6 mRNA is a biomarker upregu... [Published Multiple Sclerosis Journal current issue - 22 hours ago]
The Sidney Kimmel Foundation For Cancer Researc... [Published PRWeb - 23 hours ago]
EASL 2014: AbbVie 2-Drug Combo + Ribavirin Cure... [Published HIV and Hepatitis.com - 23 hours ago]
Enanta announces encouraging data from AbbVie's... [Published Individual.com - Apr 22 2014]
An etiologic regulatory mutation in IRF6 with l... [Published Bionity.com - Apr 22 2014]
Curing Hepatitis C: A Success Story and a Price... [Published Science-Based Medicine - Apr 22 2014]
Asthma drug and risk of MS [Published Multiple Sclerosis Research - Apr 22 2014]
IFITM proteins facilitate the entry of HCoV-OC4... [Published PNAS - Apr 22 2014]
Updated Summary: ACR Appropriateness Criteria® ... [Published National Guideline Clearinghouse - Apr 21 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
The World Market for Biosimlars (EPO, G-CSF, HG... [Published PR Newswire: Entertainment & Media - 20 hours ago]
NEW YORK, April 22, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:The World Market for Biosimlars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Editio ...
Ribosomal protein S6 mRNA is a biomarker upregu... [Published Multiple Sclerosis Journal current issue - 22 hours ago]
Background: Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system which responds to therapies targeting circulating immune cells. Objective: Our aim was to test if the T-cell activation gene expression pattern (TCAGE) we ...
Curing Hepatitis C: A Success Story and a Price... [Published Science-Based Medicine - Apr 22 2014]
Most people know about hepatitis B; babies get vaccinated for it at birth. But fewer people know about hepatitis C. C is actually more common than B, but most chronically infected people don’t know they have it. You might think ignorance is bliss, but ...
Asthma drug and risk of MS [Published Multiple Sclerosis Research - Apr 22 2014]
Use of a common asthma drug reduces your risk of developing MS? #MSBlog #MSResearch "The following records based studies showed that people who use fenoterol an asthma drug have a reduced risk of developing MS. This can be interpreted in several ways. ...
MxA levels and interferon-beta response [Published Multiple Sclerosis Research - Apr 21 2014]
Can we predict who are responders and non-responders to interferon-beta? #MSBlog #MSResearch "Interferon-beta is a cytokine (intracellular immune messenger) that binds to its receptors on cells to induce specific biological effects. It is one of the ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Simeprevir has now been approved in Russia [Published GlobeNewswire: Acquisitions News - Mar 24 2014]
Hemispherx Biopharma Reports Evidence Based Cli... [Published GlobeNewswire: Advertising News - Jan 07 2014]
Genzyme’s Lemtrada™ Approved in Canada for Trea... [Published Genzyme Press Release - Dec 13 2013]
Simeprevir finns nu tillgängligt för hepatit C-... [Published GlobeNewswire: Acquisitions News - Dec 10 2013]
Simeprevir is now available for Hepatitis C pat... [Published GlobeNewswire: Acquisitions News - Dec 10 2013]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.